

Daily evidence digest

2 March 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Prenatal and neonatal complications of COVID-19, ambulatory monitoring of COVID-19 patients, anticipating the next variant

Peer reviewed journals featured:

- A systematic review on prenatal and neonatal complications of COVID-19 [here](#)
- Meta-analysis on the effectiveness of COVID-19 vaccines against the Delta variant [here](#)
- Randomised clinical trials of sarilumab in hospitalised COVID-19 patients [here](#) and [here](#)
- A Bayesian reanalysis of a previous meta-analysis on mortality rates in hospitalised COVID-19 patients treated with tocilizumab and corticosteroids [here](#)
- Observational studies on:
 - Ambulatory monitoring of patients with COVID-19 [here](#)
 - Development and validation of a risk stratification model for severe COVID-19 in the general population [here](#)
 - Trends in mortality rates among patients with Alzheimer's disease and related dementias in the early phase of COVID-19 in the US [here](#) and associated editorial [here](#)
- An editorial on systems for turning evidence into action [here](#)

Pre-peer review articles featured:

- Comirnaty (Pfizer) vaccine effectiveness in children 5-11 and 12-17 years in New York after the emergence of the Omicron variant [here](#)

Guidance and reports

- The European Society of Clinical Microbiology and Infection Diseases published guidelines on diagnostic testing for SARS-CoV-2 [here](#)

News and blogs

- Three key questions about the next variant [here](#)
- Sanofi and GSK to seek regulatory authorisation for protein-based vaccine [here](#)
- The US Centers for Disease Control and Prevention relaxes rules on mask wearing [here](#)

[Click here](#) to subscribe to the daily evidence digest.